Töpel Ingolf, Betz Thomas, Uhl Christian, Wiesner Matthias, Bröckner Stefan, Steinbauer Markus
Vascular Surgery, Krankenhaus Barmherzige Brüder Regensburg, Germany.
Vasa. 2012 May;41(3):215-20. doi: 10.1024/0301-1526/a000188.
The current treatment standard of infected infrainguinal prosthetic vascular grafts includes total graft explantation and autologous vascular reconstruction. In the absence of appropriate autologous venous graft material prosthetic grafts with increased bacterial resistance can be used, whereas reinfection rates are still higher than after autologous reconstruction. Biosynthetic grafts have shown low postoperative infection rates when used as elective bypass material. Their higher resistance to bacterial infection could make them an alternative to replace infected prosthetic grafts in the absence of autologous material.
Between November 2009 and April 2011, 7 patients with infected infrainguinal prosthetic grafts (Szilagyi 3; 3 supragenicular and 4 infragenicular reconstructions) presented to our institution. There were 4 early (< 3 months after implantation) and 3 late infections (> 3 months after implantation. All grafts were explanted and replaced by biosynthetic grafts (Omniflow II®), because the patient had no suitable peripheral vein for complete autologous replacement. In 2 cases a composite graft with greater saphenous vein was done. In 6 cases microbiological cultures from intraoperatively obtained species were positive. The initial broad spectrum antibiotic therapy was continued according to the antibiogram for 6 to 12 weeks.
There was no early or late reinfection during follow up (mean 9 months, range 4 - 20 months). During follow up we observed graft occlusions in 3 patients (1 due to kinking of the bypass, 1 due to progressive artheriosclerotic occlusion of the outflow vessels and 1 iatrogenic by external compression with a pressure cuff during arthroscopy). There were no early or late major amputations. One patient died with pneumonia 11 months postoperatively.
In the absence of appropriate autologous material biosynthetic grafts seem to be a possible alternative to replace infected infrainguinal grafts. The different mechanical properties of biosynthetic grafts may be of certain disadvantage in infragenicular reconstructions.
目前感染性腹股沟下人工血管移植物的治疗标准包括完全移除移植物并进行自体血管重建。在缺乏合适的自体静脉移植物材料时,可以使用具有增强抗菌性的人工移植物,但其再感染率仍高于自体重建术后。生物合成移植物在用作择期旁路材料时显示出较低的术后感染率。它们对细菌感染的较高抵抗力可能使其成为在缺乏自体材料时替代感染性人工移植物的一种选择。
2009年11月至2011年4月期间,7例感染性腹股沟下人工移植物患者(Szilagyi 3型;3例为股上段和4例为股下段重建)前来我院就诊。其中4例为早期感染(植入后<3个月),3例为晚期感染(植入后>3个月)。由于患者没有合适的外周静脉进行完全自体置换,所有移植物均被移除并用生物合成移植物(Omniflow II®)替代。2例患者进行了大隐静脉复合移植物手术。6例患者术中获取的标本微生物培养呈阳性。根据药敏结果继续进行初始广谱抗生素治疗6至12周。
随访期间(平均9个月,范围4 - 20个月)无早期或晚期再感染。随访期间,我们观察到3例患者出现移植物闭塞(1例因旁路扭结,1例因流出道血管进行性动脉粥样硬化闭塞,1例在关节镜检查期间因压力袖带外部压迫导致医源性闭塞)。无早期或晚期大截肢情况。1例患者术后11个月死于肺炎。
在缺乏合适的自体材料时,生物合成移植物似乎是替代感染性腹股沟下移植物的一种可能选择。生物合成移植物的不同机械性能在股下段重建中可能存在一定劣势。